https://www.selleckchem.com/pr....oducts/BMS-754807.ht
There was no significant difference in access between "innovative" and "non-innovative" antibacterials. Median annual sales in the first launched market (generally the US) for these 18 antibiotics were low, $16.2M. Patient access to new antibacterials is limited in some high-income countries including Canada, Japan, France, Germany, Italy, and Spain. With low expected sales, companies may have decided to delay or forego commercialization due to expectations of insufficient profitability. Patient access to new antibacterials is limite
Like
Comment
Share
